Close

Novel Ovarian Cancer Treatment By GSK Approved In Singapore

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Receptor Grade IGF-1 LR3: Expansive Research Potential

Receptor Grade IGF-1 LR3, an engineered analog of Insulin-like...

API China 2025 kicks off with Industry Buzz on Day One

At the China Import and Export Fair Complex in...

Automated Fluid Transfer in Biomanufacturing Systems

Automation in Fluid Transfer: From Manual to Modular Systems...

FDA Plans to Deploy AI Tools for Scientific Reviews

The US Food and Drug Administration has announced plans...

The oral, once-daily Zejula (niraparib) tablet, a first-line and recurrent upkeep care for women with advanced epithelial high-grade ovarian, fallopian tube, or primary peritoneal cancer who are in full or partial remission after platinum-based chemotherapy, has been approved by the Health Sciences Authority, according to a statement from GlaxoSmithKline (GSK) Singapore.

Regardless of whether a patient has a BRCA mutation, Zejula is now the only poly (ADP-ribose) polymerase (PARP) inhibitor licenced in Singapore to be used as a single therapy for patients with advanced and recurrent ovarian cancer.

As of March 2022, Zejula is accessible for the first ovarian cancer (PRIMA) in 44 nations and 2 Special Administration Regions. Zejula is also being tested against a variety of tumour types and in combination with a number of different treatments. Notably, it is now undergoing testing in a Phase III clinical research called ZEST to examine its potential for treating individuals with breast cancers that have the specialised treatment needs of triple-negative breast cancer (TNBC) or BRCAm HER2- breast cancer.

Latest stories